On Nov 06, major Wall Street analysts update their ratings for $Exact Sciences (EXAS.US)$, with price targets ranging from $75 to $85.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and adjusts the target price from $88 to $75.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $80 to $75.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $80 to $82.
Piper Sandler analyst David Westenberg maintains with a buy rating, and maintains the target price at $85.
CCORF analyst Kyle Mikson CFA maintains with a buy rating, and adjusts the target price from $95 to $75.
Furthermore, according to the comprehensive report, the opinions of $Exact Sciences (EXAS.US)$'s main analysts recently are as follows:
Exact Sciences' Q3 results did not meet expectations, and its FY24 guidance was reduced due to unsatisfactory performance coupled with multiple challenges anticipated in Q4. Following the guidance reduction, the company's stock experienced a 30% decline in after-market trading. This decline is thought to be more indicative of market positioning and growth concerns. Despite these challenges, there is a belief that Exact Sciences can bounce back from the recent downturn.
The company's challenges are seen as short-lived, despite the recognition of the recent 'low-quality results'.
Exact Sciences has faced challenges leading to lower than expected Q3 results and a reduced outlook for Q4. These challenges include decreased demand at primary care facilities, effects from hurricanes, slower progress for new representatives, and transitional hurdles with ExactNexus. There is a growing concern regarding whether the stool-based market is experiencing a structural slow down. Moreover, there is limited clarity regarding the future performance of Cologuard and blood-based assays, positioning Exact Sciences as a company that heavily relies on trust.
Exact Sciences encountered a third-quarter revenue shortfall and a significant revision of its guidance, marking an unusual operational misstep in commercial execution. This was influenced by a deceleration in orders between early August and late October, along with hurricane-related impacts that affected up to 18% of orders, and a delayed acceleration in the productivity of newly hired sales representatives.
Exact Sciences' recent quarterly performance fell short of expectations, coupled with a significant reduction in their forecast for the next quarter. This has been attributed to challenges in commercial execution, the impact of hurricanes, and a slower increase in productivity.
Here are the latest investment ratings and price targets for $Exact Sciences (EXAS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$精密科學 (EXAS.US)$的評級，目標價介於75美元至85美元。
美銀證券分析師Michael Ryskin維持買入評級，並將目標價從88美元下調至75美元。
花旗分析師Patrick B Donnelly維持買入評級，並將目標價從80美元下調至75美元。
TD Cowen分析師Daniel Brennan維持買入評級，並將目標價從80美元上調至82美元。
派傑投資分析師David Westenberg維持買入評級，維持目標價85美元。
CCORF分析師Kyle Mikson CFA維持買入評級，並將目標價從95美元下調至75美元。
此外，綜合報道，$精密科學 (EXAS.US)$近期主要分析師觀點如下：
精密科學的Q3業績未達預期，FY24指引由於表現不佳以及預計Q4會面臨多重挑戰而有所下調。在指引下調後，公司股票經歷了盤後交易中30%的下跌。這種下跌被認爲更多地反映了市場定位和增長方面的擔憂。儘管面臨這些挑戰，人們相信精密科學能夠從最近的低迷中恢復。
公司的挑戰被視爲短暫的，儘管承認有最近的「低質量結果」。
精密科學麪臨挑戰，導致Q3業績低於預期，Q4前景也有所下調。這些挑戰包括初級保健設施需求下降、颶風的影響、新代表的進展較慢，以及ExactNexus的過渡障礙。對基於糞便的市場是否正經歷結構性放緩存在越來越大的擔憂。此外，對Cologuard和基於血液的檢測的未來表現缺乏明確性，將精密科學定位爲極度依賴信任的公司。
精密科學遇到了第三季度營業收入不足和指引的重大修訂，在商業執行方面出現了飛凡的操作失誤。這主要受到了8月初至10月底訂單放緩的影響，以及影響多達18%訂單的颶風，以及新招聘銷售代表的生產力延遲加速。
精密科學最近季度業績低於預期，加上對下一季度預測的顯著減少。這被歸因於商業執行方面的挑戰，颶風的影響以及生產力增長放緩。
以下爲今日5位分析師對$精密科學 (EXAS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
